# Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Source: https://onco.cc/trials/nct00186628/  
OnCo record `nct00186628` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rituximab, Filgrastim and Granisetron in Leukaemia and Mantle cell lymphoma, run by Stanford University, completed.

## Summary

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD is a phase 2 interventional study registered as NCT00186628 by Stanford University, with 36 participants recorded, started 2005-06 and reaching its primary completion in 2010-11. Interventions recorded: Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, Mycophenylate mofetil, Filgrastim, Granisetron, Solumedrol, Acetaminophen, Diphenhydramine, Hydrocortisone. Conditions recorded: Leukemia, Mast-Cell, Mantle-cell Lymphoma.

Linked to the drug Granisetron because the registry names it among its interventions and Leukaemia and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00186628
- Phase: 2
- Setting: An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation
- Sponsor: Stanford University
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT00186628: https://clinicaltrials.gov/study/NCT00186628

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Granisetron](https://onco.cc/drugs/granisetron/), [Rituximab](https://onco.cc/drugs/rituximab/)

---
JSON: https://onco.cc/api/v1/entities/nct00186628.json